Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immunovant (IMVT) stock

Learn how to easily invest in Immunovant stock.

Immunovant, Inc
NASDAQ: IMVT - USD
BIOTECHNOLOGY
$10.20
+$0.21 (+2.10%)

Immunovant, Inc is a biotechnology business based in the US. Immunovant shares (IMVT) are listed on the NASDAQ and all prices are listed in US Dollars. Immunovant employs 68 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Immunovant

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMVT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immunovant stock price (NASDAQ: IMVT)

Use our graph to track the performance of IMVT stocks over time.

Immunovant shares at a glance

Information last updated 2021-07-24.
Latest market close$15.16
52-week range$9.31 - $53.75
50-day moving average $10.63
200-day moving average $19.02
Wall St. target price$21.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.25

Buy Immunovant shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immunovant stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunovant price performance over time

Historical closes compared with the close of $15.16 from 2021-05-28

1 week (2021-07-16) N/A
1 month (2021-06-25) 32.87%
3 months (2021-04-27) -5.78%
6 months (2021-01-23) N/A
1 year (2020-07-23) N/A
2 years (2019-07-23) N/A
3 years (2018-07-23) N/A
5 years (2016-07-23) N/A

Immunovant financials

Gross profit TTM $0
Return on assets TTM -25.9%
Return on equity TTM -44.25%
Profit margin 0%
Book value $4.00
Market capitalisation $978.8 million

TTM: trailing 12 months

Shorting Immunovant shares

There are currently 5.7 million Immunovant shares held short by investors – that's known as Immunovant's "short interest". This figure is 5.9% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Immunovant shares can be evaluated.

Immunovant's "short interest ratio" (SIR)

Immunovant's "short interest ratio" (SIR) is the quantity of Immunovant shares currently shorted divided by the average quantity of Immunovant shares traded daily (recently around 2.1 million). Immunovant's SIR currently stands at 2.69. In other words for every 100,000 Immunovant shares traded daily on the market, roughly 2690 shares are currently held short.

However Immunovant's short interest can also be evaluated against the total number of Immunovant shares, or, against the total number of tradable Immunovant shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunovant's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Immunovant shares in existence, roughly 60 shares are currently held short) or 0.1622% of the tradable shares (for every 100,000 tradable Immunovant shares, roughly 162 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunovant.

Find out more about how you can short Immunovant stock.

Immunovant share dividends

We're not expecting Immunovant to pay a dividend over the next 12 months.

Immunovant overview

Immunovant, Inc. , a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. .

Stocks similar to Immunovant

Frequently asked questions

What percentage of Immunovant is owned by insiders or institutions?
Currently 61.009% of Immunovant shares are held by insiders and 41.427% by institutions.
How many people work for Immunovant?
Latest data suggests 68 work at Immunovant.
When does the fiscal year end for Immunovant?
Immunovant's fiscal year ends in March.
Where is Immunovant based?
Immunovant's address is: 320 West 37th Street, New York, NY, United States, 10018
What is Immunovant's ISIN number?
Immunovant's international securities identification number is: US45258J1025
What is Immunovant's CUSIP number?
Immunovant's Committee on Uniform Securities Identification Procedures number is: 42227C102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site